

The transcription factor Six1a plays an essential role in the craniofacial myogenesis of zebrafish

Cheng-Yung Lin, Wei-Ta Chen, Hung-Chieh Lee, Ping-Hsi Yang, Hsin-Jung Yang, Huai-Jen Tsai*

Institute of Molecular and Cellular Biology, National Taiwan University, Room 307, Fisheries Science Building, No. 1, Section 4, Roosevelt Road, Taipei, 106, Taiwan

ARTICLE INFO

Article history:

Received for publication 14 November 2008

Revised 15 April 2009

Accepted 24 April 2009

Available online xxx

Keywords:

Six1a

Myf5

Myod

Cranial myogenesis

Zebrafish

ABSTRACT

Transcription factor Six1a plays important roles in morphogenesis, organogenesis, and cell differentiation. However, the role of Six1a during zebrafish cranial muscle development is still unclear. Here, we demonstrated that Six1a was required for sternohyoideus, medial rectus, inferior rectus, and all pharyngeal arch muscle development. Although Six1a was also necessary for *myod* and *myogenin* expression in head muscles, it did not affect *myf5* expression in cranial muscles that originate from head mesoderm. Overexpression of *myod* enabled embryos to rescue all the defects in cranial muscles induced by injection of *six1a*-morpholino (MO), suggesting that *myod* is directly downstream of *six1a* in controlling craniofacial myogenesis. However, overexpression of *six1a* was unable to rescue arch muscle defects in the *tbx1*- and *myf5*-morphants, suggesting that *six1a* is only involved in myogenic maintenance, not its initiation, during arch muscle myogenesis. Although the craniofacial muscle defects caused by *pax3*-MO phenocopied those induced by *six1a*-MO, injection of *six1a*, *myod* or *myf5* mRNA did not rescue the cranial muscle defects in *pax3* morphants, suggesting that *six1a* and *pax3* do not function in the same regulatory network. Therefore, we proposed four putative regulatory pathways to understand how *six1a* distinctly interacts with either *myf5* or *myod* during zebrafish craniofacial muscle development.

© 2009 Published by Elsevier Inc.

Introduction

During embryogenesis, the trunk and limb muscles originate from somites, which are epithelial structures in the mesoderm flanking the neural tube, whereas head muscles mostly originate from cranial mesoderm (Noden and Francis-West, 2006). Three groups contribute to the craniofacial skeletal muscles: (1) branchial arch muscles, which are derived from the unsegmented head mesoderm and operate the jaw, facial expression, pharyngeal, laryngeal and gill function; (2) most extraocular muscles, which develop from the prechordal mesoderm and control eye movement; and (3) those muscles derived from progenitor cells in the occipital somites of trunk, which move into the head and give rise to muscles of the tongue and neck (Noden and Francis-West, 2006; Chai and Maxson, 2006; Shih et al., 2007).

Despite the varied origins of these muscles, all of them are controlled by myogenic regulatory factors (MRFs) (Buckingham, 2006). Proliferative myoblasts, which have undergone initial myogenic commitment, are marked by the expressions of Myf5 and MyoD, while later myogenic differentiation is marked by Myogenin and MRF4. However, because of the different origins of these muscle cells, MRFs are regulated differently in the head and trunk. For example, mice lacking Myf5 and Pax3 do not develop skeletal muscle in the trunk and limb, whereas they do develop normal head muscles

(Tajbakhsh et al., 1997). Taking another example, Lbx1/Pax7/Paraxis in chick are necessary for trunk myogenesis, but they are not necessary for head myogenesis (Mootoosamy and Dietrich, 2002). In fact, the Wnt signals, which promote trunk myogenesis, have been proven to block head myogenesis in chick (Tzahor et al., 2003). In zebrafish, we have clearly defined the distinct functions of Myf5 and Myod that regulate head muscle development, and we have demonstrated that they exhibit their own regulatory pathways (Lin et al., 2006). Although myogenic progression is similar in all developing muscle groups, it seems, therefore, that the specification of cells just before myoblast differs significantly between head and trunk (Rawls and Olson, 1997; Mootoosamy and Dietrich, 2002).

Only a few factors have been reported to play roles in head myogenesis, and we enumerate them here. Mice lacking Capsulin and *myoR* fail to express *myf5* in the first arch and lose a subset of mandibular arch-derived muscle (Lu et al., 2002). It has been found that *tbx1*, which is expressed in the premyoblast mesoderm in the first and second branch arch, is required for the development of some head muscles (Kelly et al., 2004; Dastjerdi et al., 2007). Although *bmp4* promotes cardiac differentiation, it also inhibits head skeletal muscle differentiation (Tirosh-Finkel et al., 2006). Similarly, *fgf8* is shown to promote branchiomeric muscle development, but it inhibits extraocular muscle development (von Scheven et al., 2006). Finally, *pitx2* is a paired-related homeobox gene, which is required for the expression of the premyoblast specification markers *tbx1*, *tcf21* (Capsulin), and *msc* (MyoR) to set up the premyoblast in the first branch arch (Dong et al.,

* Corresponding author. Fax: +886 2 2363 8483.

E-mail address: hjtsai@ntu.edu.tw (H.-J. Tsai).

2006; Shih et al., 2007; L'Honore et al., 2007). However, it remains unclear what additional factors may be involved in head myogenesis.

The *six* gene is a vertebrate homolog of the *Drosophila* homeobox gene *sine oculis* (*so*) and plays important roles in morphogenesis, organogenesis, and cell differentiation (Kawakami et al., 2000). Six protein is a transcription factor that contains two conserved domains, the Six domain (SD) and the homeodomain (HD). Both domains are required for specification through binding DNA and cooperative interaction with cofactors (Kawakami et al., 1996; Chen et al., 1997; Pignoni et al., 1997). For example, *Drosophila so* is required for eye formation through binding the synergistic regulatory network, such as *eyeless* (*Pax*), *eyes absent* (*Eya*) and *dachshund* (*Dach*) (Chen et al., 1997; Pignoni et al., 1997).

In vertebrates, Six protein displays a similar regulatory network during myogenesis and development of the metanephric kidney and inner ear (Heanue et al., 1999; Xu et al., 1999; Xu et al., 2003; Li et al., 2003). Moreover, Six protein is reported to directly control the expressions of *myf5* and *myogenin* through binding at the MEF3 in their promoters (Spitz et al., 1998; Giordani et al., 2007). There are six Six genes (*Six1* to *Six6*) in mouse and human genomes (Kawakami et al., 2000). *Six1* is expressed from E8 stage and throughout skeletal muscle development in mouse embryos (Grifone et al., 2004). *Six1* and *Six4* are expressed as overlapping in muscle territories, such as dermomyotome, myotome, limb bud and migrating muscle precursors (Ozaki et al., 2001; Laclef et al., 2003). *Six1*-knockout fetuses suffer from muscle hypoplasia (Laclef et al., 2003), whereas *Six1* and *Six4* double knockout embryos appear to have more severe muscle defects, especially in leg muscles (Grifone et al., 2005), suggesting that *Six4* shares a common function with *Six1* during myogenesis. Furthermore, in both *Six1*^{-/-}*Six4*^{-/-} and *Eya1*^{-/-}*Eya2*^{-/-} double mutants, *pax3* fails to express in the hypaxial dermomyotome, which then causes cell death and reduces muscle progenitor cells in the limbs (Grifone et al., 2005; Grifone et al., 2007). In zebrafish, six members of the *six* gene have been defined: *six1a-1b*, *six2-2.1*, *six3a-3b*, *six4.1-4.3*, *six7* and *six9* (Kobayashi et al., 1998, 2000, 2001; Drivenes et al., 2000; Wargelius et al., 2003; Bessarab et al., 2004, 2008). Both *six1a* and *six4.2* are expressed in the presomitic mesoderm, somites and pectoral fin bud. Moreover, Bessarab et al. (2004) reported that *six1a* expression is regulated by the Notch pathway during trunk muscle differentiation. Knockdown of *six1a* causes *myogenin* expression to be reduced in somites, resulting in abnormal differentiation of trunk fast muscles (Bessarab et al., 2008). They also demonstrated that the *six1a* transcript is expressed in craniofacial muscle. More importantly, it has been reported that the *six1a* gene is involved in branchio-oto-renal syndrome (Ruf et al., 2004). Therefore, detailed knowledge about the mechanisms controlling molecular interaction among genes involved in head muscle development should not only give insight into craniofacial morphogenesis but also help in the development of therapies designed to treat clinical syndromes affecting head and facial development. However, the function that Six1a plays in head muscle development is still unknown.

In this study, we focus on the role of Six1a in head myogenesis. When Six1a is absent by injection of *six1a*-specific morpholino (MO), we show that *myf5* fails to express in the cranial muscles that originate from trunk paraxial mesoderm, whereas *myf5* continues to be normally expressed in cranial muscles that originate from head mesoderm. In contrast, *myod* is lost in the cranial muscles that originate both from trunk and head mesoderm. We also demonstrate that injection of *myod* mRNA can rescue the *six1a*-MO-induced defect, but that injection of *myf5* mRNA could only rescue the muscle defects that originate from trunk paraxial mesoderm. We prove that the function of Six1a is equivalent to Pax3 and that Six1a is not involved in the Tbx1 pathway. Furthermore, we propose four putative regulatory pathways to demonstrate that *six1a* interacts separately with either *myf5* or *myod* to modulate the development of craniofacial muscles in zebrafish.

Materials and methods

Fish embryos

The wild-type AB strain (University of Oregon, Eugene, OR) and the transgenic line Tg(α -actin:RFP) (Lin et al., 2006) of zebrafish (*Danio rerio*) were used. The culture condition, embryo stage, egg production and collection were described previously (Lin et al., 2006). Fluorescent signal in embryos was observed under a fluorescent stereomicroscope (MZ FLIII, Leica) equipped with 583 nm (emission) filters.

Whole-mount *in situ* hybridization

Whole-mount *in situ* hybridization has been described previously (Lee et al., 2006), except that the following genes were used as probes: *six1a* (Bessarab et al., 2004); *myf5*, *myod*, *myogenin*, *et1* (Miller et al., 2000); *fgf3*, *dlx2* (Akimenko et al., 1994); *tbx1* (Piotrowski et al., 2003); *pax3* (Seo et al., 1998) and *eya1* (Sahly et al., 1999) cDNAs (GenBank Accession Nos. NM207095, NM131576, NM131262, NM131006, AF281858, NM131291, U03875, NM183339, AF014366, and BC154187, respectively).

MOs for blocking translation and mRNAs for rescue experiments

MOs designed specifically as translational inhibitors of *six1a* were (1) *six1a*-MO (Nica et al., 2006), 5'-CGAAAGAAGGCAACATTGACATGAC-3', which is complementary to nucleotides (nt) 142–166 of zebrafish *six1a* cDNA (GenBank Accession No. NM207095) and was injected at the concentration of 8, 6, 4, 2, or 1 ng per embryo; (2) UM-MO (Bessarab et al., 2008), 5'-TCTCCTCTGGATGCTA-CGAAGGAAG-3', which is complementary to nt 93–117 of zebrafish *six1a* cDNA (GenBank Accession No. NM207095) and was injected at 8 ng per embryo; and (3) SM-MO (Bessarab et al., 2008), 5'-CGCTTAAT-TACCITTCITTCGCCTC-3', which is complementary to nt 87073–87097 (intron sequence is underlined) of the clone DKEY-225H23 (GenBank Accession No. BX649231), binding the splice donor site of *six1a* pre-mRNA, and was injected at 8 ng per embryo. Regarding MOs that were designed specifically as translational inhibitors of MRFs, they were (1) *myf5*-MO, 5'-TCTGGGATGTGGAGAATACGTCCAT-3', which is complementary to nt 44–68 of zebrafish *myf5* cDNA (GenBank Accession No. NM131576) and was injected at 4 ng per embryo; and (2) *myod*-MO (Lin et al., 2006), 5'-ATATCCGAC-AACTCCATCTTTTTTG-3', which is complementary to nt 172–196 of zebrafish *myod* cDNA (GenBank Accession No. NM131262) and was injected at 4 ng per embryo. Regarding MOs that were designed specifically as translational inhibitors of *tbx1*, *pax3* and *eya1*, they were (1) *tbx1*-MO, 5'-GGGCTTGATATTGCTGAAA-TCATTC-3', which is complementary to nt 359–383 of zebrafish *tbx1* cDNA (GenBank Accession No. NM183339) and was injected at 10 ng per embryo; (2) *pax3*-MO (Lee et al., 2006), 5'-ACGAAAAAAGGATGCACGAAGCACT-3', which is complementary to nt 241–265 of zebrafish *pax3* cDNA (GenBank Accession No. AF014366) and was injected at 3 ng per embryo; and (3) *eya1*-MO (Bricaud and Collazo, 2006), 5'-AGCTAGATCCTGCATTTCCATAGAC-3', which is complementary to nt 274–298 of zebrafish *eya1* cDNA (GenBank Accession No. AF014366) and was injected at 10 ng per embryo. All MOs were prepared at a stock concentration of 1 mM and were diluted to the desired concentrations for microinjection.

In order to further prove the specific effectiveness of *six1a*-, *myod*- and *myf5*-MO, we designed the following synthetic mRNA: (1) *six1a-egfp* mRNA, in which the *six1a* cDNA, including *six1a*-MO target sequence, is fused in frame with *egfp* cDNA; (2) *myod-egfp* mRNA, in which the *myod* cDNA, including *myod*-MO target sequence, is fused in frame with *egfp* cDNA; and (3) *myf5-MO-target-egfp* mRNA, in which the *myf5*-MO target sequence is fused in frame with *egfp* cDNA. Regarding that the introduced *six1a* mRNA is not bound by *six1a*-MO during the rescue experiment, we designed (1) a wobble *six1a* mRNA, 213

214 in which we changed the nt 145–166 of zebrafish *six1a* cDNA (GenBank
215 Accession NO. NM207095) from 5'-ATGCAATGTTCCTTCTTCG-3' to
216 5'-ATGAGTATGCTCCCGAGCTTCG-3', but without altering the amino
217 acid residues; and (2) a wobble *six1a-egfp* mRNA, in which the wobble
218 *six1a* cDNA was fused in frame with *egfp* cDNA. Capped mRNA of
219 wobble *six1a* was synthesized according to the protocols of the
220 manufacturer (Epicentre). The mRNAs of *myf5* and *myod* were also
221 synthesized. The generated mRNAs were diluted with distilled water to
222 110 ng/μl and 66 ng/μl for *six1a* mRNA, to 44 ng/μl and 22 ng/μl for
223 *myf5* mRNA and to 22 ng/μl for *myod* mRNA (Lin et al., 2006). Each
224 time, approximately 2.3 nl of solution was injected into the one-cell
225 stage of zebrafish embryos.

226 Western blot analysis

227 The Western blot was performed after the total proteins were
228 analyzed on a 12% SDS-PAGE by following the procedures described
229 previously (Lee et al., 2007), except that the yolk was removed, and
230 the antibodies of anti-Six1a (abcan, ab22072) and anti-Glyceraldehyde
231 3-phosphate dehydrogenase (ABBIOTEC, 250504) were used at the
232 dilution of 1:1000.

233 Results

234 Expression patterns of *six1a*, *myf5* and *myod* in zebrafish head 235 muscle development

236 To study the roles of Six1a during cranial muscle development,
237 we first analyzed the spatiotemporal expression of *six1* from 24 to
238 72 hpf and made a comparison with the expression patterns of
239 some MRFs, particularly *myf5* and *myod*. At 24 hpf, *six1a* was
240 detected in the olfactory placode (olp), otic vesicle (ov), anterior
241 lateral line and vestibular ganglia (allg) (Fig. 1A), which was
242 consistent with what was reported by Bessarab et al. (2004). We
243 also noted that *six1a* was only expressed in the neural ectoderm,
244 but not in the cranial mesoderm, during 24 hpf. However, *myf5*, but
245 not *myod*, were detected in the cranial muscle precursors during
246 24 hpf (Figs. 1B, C). At 32 hpf, *six1a* initiated expression in
247 branchial arch and in extraocular muscle primordium of the medial
248 rectus (mr) and inferior rectus (ir) (Fig. 1D), while *myf5* started to
249 gradually reduce its expression in the first branchial arch, but began
250 to express in the extraocular muscle primordium inferior oblique (io)
251 and superior oblique (so) (Fig. 1E). At the same time, *myod*
252 transcripts were initially detected in the head muscle primordia
253 of the mr, ir, lateral rectus (lr), and first branchial arch mesoderm core
254 (Fig. 1F), which was similar to the expression pattern of *six1a*. At
255 36 hpf, *six1a* was strongly expressed in the branchial arch (Fig. 1G),
256 while the *myf5* transcripts were gradually decreased in the arch
257 region (Fig. 1H). However, *myod* was now detected in head muscles
258 derived from the first (masticatory plate, MP; intermandibularis,
259 IM) and the second arch mesoderm cores (constrictor hyoideus
260 dorsalis, CHD; constrictor hyoideus ventralis, CHV) (Fig. 1I). This
261 result was consistent with the report of Schilling and Kimmel
262 (1994). At 72 hpf, all cranial muscles were *six1a*- (Figs. 1J, L) and
263 *myod*-positive (Figs. 1K, M).

264 Comparing the expression patterns of *six1a*, *myf5* and *myod* during
265 the head muscle development of zebrafish, we concluded that *six1a*
266 was expressed in all cranial muscles. The expression stage of *six1a* in
267 hyoid (1st), mandibular (2nd), and branchial arch (3rd) was later than
268 that of *myf5*, but obviously earlier than that of *myod*. In extraocular
269 muscle, *six1a* started to express in mr and ir primordia and sustained
270 its expression to the later stage of 72 hpf, which was similar to *myod*,
271 but different from *myf5*, which was expressed in io and so primordia.
272 Thus, we can further conclude that the expression of *myf5* is earlier
273 than that of *six1a* in the cranial mesoderm, whereas the expression of
274 *six1a* is earlier than that of *myod* in the arches.

275 *Six1a* is involved in zebrafish cranial muscle development

276 To understand whether *six1a* plays roles in craniofacial muscle
277 development, we used a transgenic line, Tg(α -actin:*RFP*), in which the
278 RFP reporter is labeled in all craniofacial muscles (Figs. 2A, B), as
279 previously reported (Lin et al., 2006). When the embryos derived from
280 this line were injected with *six1a*-MO, we observed that the muscle
281 primordia of extraocular muscles mr and ir, all arch muscles and sh
282 were missing at 72 hpf (Figs. 2C, D), whereas the muscle primordium of
283 so, io, sr, and lr, and some remnants of arch muscle cells, were all
284 normal and presented as RFP-positive (Figs. 2A, B). Furthermore,
285 besides *six1a*-MO, we also designed two other types of morpholinos,
286 UM-MO and SM-MO, to specifically knockdown the translation of
287 *six1a* mRNA. The defective phenotype induced by injection of either
288 UM-MO or SM-MO was similar to that of injection of *six1a*-MO
289 (Supplemental Fig. S1). Western blot analysis proved that the Six1a
290 expression level was greatly reduced in the *six1a*-MO-injected
291 embryos (Supplemental Fig. S2). In addition, we co-injected a wobble
292 *six1a-egfp* mRNA with a *six1a*-MO, and the Six1a-GFP fusion protein
293 was detected in embryos (Supplemental Fig. S3), indicating that the
294 injected *six1a*-MO cannot inhibit the translation of the introduced
295 wobble *six1a-egfp* mRNA. Furthermore, co-injection of *six1a*-MO with
296 wobble *six1a*-mRNA, but not *egfp* mRNA, enabled embryos to rescue
297 the defective phenotypes induced by *six1a*-MO and resulted in the
298 normal development of all head muscles (Figs. 2E, F; and Table 2). We
299 also noticed that the degree of defective phenotype induced by *six1a*-
300 MO was dose-dependent (Table 1). Overall, evidence indicates that
301 the defects induced by *six1a*-MO are specific and we therefore
302 concluded that *six1a* is necessary for the development of extraocular
303 muscles mr and ir, all arch muscles and sh, which migrate from trunk
304 and contribute to head muscle. 304

305 *Six1a* functions with *Myf5* and *Myod* in cranial muscle development, but 306 in different modulations

307 Lin et al. (2006) categorized all zebrafish cranial muscles into three
308 groups and defined three regulatory pathways involved in cranial
309 muscle development. Among them, the extraocular muscles so and io,
310 the dorsal pharyngeal arch muscles lap, do, am, ah and ao, and the
311 trunk migratory head muscle sh, are categorized as Group I, whose
312 primordial cells require Myf5 to activate their downstream MRFs, such
313 as *myod* and *myogenin*. In this study, we found that *myf5* was normally
314 expressed in pharyngeal arch muscle precursors of the *six1a*-MO-
315 injected embryos during 36–48 hpf (Figs. 2I vs. M and J vs. N). In
316 addition, compared to the wild-type embryos, the expressions of
317 *myf5*, *myod* and *myogenin* remained unchanged in the extraocular
318 muscles so and io of *six1a* morphants (Figs. 2J vs. N, K vs. O, and L vs. P).
319 However, the expressions of *myod* and *myogenin* were greatly reduced
320 in the pharyngeal arch muscle precursors, lap, do, am, ah, and ao, of
321 *six1a*-MO-injected embryos at 48 hpf (Figs. 2K vs. O and L vs. P),
322 suggesting that Six1a is required for the normal expressions of *myod*
323 and *myogenin* in the precursors of dorsal pharyngeal arch muscles. On
324 the other hand, the primordial muscle sh, which originates from trunk,
325 lost both *myf5* and *myod* expression in the *six1a* morphants (Figs. 5B
326 vs. E and C vs. F), suggesting that Six1a is required for the expressions
327 of *myf5* and *myod* in sh primordial muscle. 327

328 The extraocular muscle lr and the ventral pharyngeal arch muscles
329 ima, imp, ih and hh are categorized as Group II, whose primordial cells
330 are *myf5*-expressed precursors and require *myod* to play a major role in
331 myogenesis. Both *myf5* and *myod* are necessary for the development of
332 Group II precursors. Here, we revealed that *myf5* was normally expressed
333 in the precursor of pharyngeal arch muscles of *six1a* morphants at 36–
334 48 hpf, compared to the wild-type embryos. In addition, the *myod* and
335 *myogenin* expressions remained unchanged in the extraocular muscle lr
336 of *six1a* morphants at 48 hpf (Figs. 2K vs. O and L vs. P). However, the
337 *myod* and *myogenin* expressions were totally lost in the ventral 337




Fig. 1. The temporal expressions of *six1a*, *myf5* and *myod* during cranial muscle development of zebrafish. The temporal expressions of *six1a* (A, D, G, J, L), *myf5* (B, E, H) and *myod* (C, F, I, K, M) transcripts of zebrafish were analyzed by whole-mount *in situ* hybridization in embryos from lateral view (A–C) and ventral view (D–M). The transcript of *six1a* in the olp, ov, and allg at 24 hpf (A); in the mr, ir, 1st, 2nd, and 3rd arches at 32 and 36 hpf (D, G); and in all the cranial muscles at 72 hpf (J, L). The *myf5* transcript was detected in the craniofacial region at 24 hpf (B, arrow); in the so, io, 2nd and 3rd arches at 32 hpf (E); and in the so, io, and 3rd arches at 36 hpf (H). Although the *myod* was not expressed in the craniofacial muscles at 24 hpf (C), it was detected in the mr/ir, lr, and 1st arch at 32 hpf (F); in the mr, ir, sr, lr, MP, IM, CHD, and CHV at 36 hpf (I); and in all the cranial muscles at 72 hpf (K, M). The schematic diagram illustrates the expression of *six1a* in the cranial muscles during 32–72 hpf (N). ah, adductor hyoideus; allg, anterior lateral line and vestibular ganglia; am, adductor mandibulae; ao, adductor operculi; do, dilator operculi; dpw1–5, dorsal pharyngeal wall 1–5; hh, hyohyoideus; ih, interhyoideus; ima, intermandibularis anterior; imp, intermandibularis posterior; io, inferior oblique; ir, inferior rectus; lap, levator arcus palatini; lr, lateral rectus; mr, medial rectus; olp, olfactory placode; ov, otic vesicle; sh, sternohyoideus; so, superior oblique; sr, superior rectus and tv 1–5, transversus ventralis 1–5. CHD: the constrictor hyoideus dorsalis, which differentiates to ah and ao; CHV: the constrictor hyoideus ventralis, which differentiates to ih and hh; IM: the intermandibularis, which differentiates to ima and imp; MP: the masticatory plate, which differentiates to CD and am. CD: the constrictor dorsalis, which differentiates to lap and do.

338 pharyngeal arch muscles ima, imp, ih and hh in the *six1a* morphants at
339 48 hpf (Figs. 2K vs. O and L vs. P), suggesting that *Six1a* affects *myod*
340 expression in the ventral pharyngeal arch muscle of zebrafish.

341 The extraocular muscles sr, mr and ir belong to Group III, whose
342 primordial cells require *myod*, but not *myf5*, as a major factor in
343 muscle development. The expressions of *myod* and *myogenin* in the
344 extraocular muscle sr of the *six1a*-MO-injected embryos appeared the
345 same as the extraocular muscle sr of the wild-type embryos (Figs. 2K
346 vs. O and L vs. P). However, the extraocular muscles mr and ir of the
347 *six1a*-MO-injected embryos were completely lost when observed at
348 48 hpf (Figs. 2K vs. O and L vs. P). This evidence suggests that *Six1a*
349 modulates *myod* expression in extraocular muscles mr and ir.

350 Taken together, during craniofacial muscle development of zebra-
351 fish, we conclude that *Six1a* is required for (1) *myf5* expression in
352 trunk migratory head muscle sh and (2) *myod* expression in the
353 extraocular muscles mr and ir in all pharyngeal arch muscles and the
354 trunk migratory head muscle sh.

355 *The defective pharyngeal arch muscles are induced specifically by loss*
356 *of Six1a*

357 Pharyngeal arch is developed from three germ layers: the
358 mesoderm core, the endoderm pharyngeal pouch and the ectoderm
359 neural crest cells (Graham and Smith, 2001). It was necessary to




Fig. 2. *Six1a* is required for the development of mr, ir, sh and all pharyngeal muscles. Embryos derived from the transgenic line Tg(α -actin:RFP) (A–H), all of whose skeletal muscles appear as red fluorescent protein (RFP), were injected with 8 ng of *six1a*-morpholino oligonucleotide (MO) to specifically inhibit *six1a* mRNA translation. RFP signal was detected only in the so, io, sr, Ir, and remnant dorsal branchial arch muscle (white star) primordia in the *six1a*-MO-injected embryos (A vs. C and B vs. D). When embryos were injected with 8 ng of *six1a*-MO together with 150 pg of *six1a* mRNA, results showed that the defective muscle primordia induced by *six1a*-MO were rescued and appeared as RFP-labeled muscles (E, F); the rescued muscles are marked in green typeface). In contrast, the rescue experiment failed when embryos were injected with 8 ng of *six1a*-MO with 200 pg of *gfp* mRNA (G, H), suggesting that the defects of *six1a* morphants were specific. The expressions of *myf5* (I, J, M, N), *myod* (K, O), and *myogenin* (L, P) were also observed at the stages indicated. When wild-type embryos were injected with *six1a*-MO, *myf5* was expressed normally in the *six1a* morphants, both at 36- (I vs. M) and at 48-hpf (J vs. N), except sh. On the other hand, the expressions of *myod* (K vs. O) and *myogenin* (L vs. P) were decreased in the extraocular io, so, sr and Ir in the *six1a* morphants at 48 hpf. Weak signals of *myod* and *myogenin* were also noticed in the remnant dorsal branchial muscles (black stars) of *six1a* morphants. The schematic diagram illustrates the cranial muscle defects in *six1a* morphants and compares the expressions of *myf5*, *myod* and *myogenin* between wild-type (upper row, Q) and *six1a* morphants (lower row, Q). Lateral view: A, C, E, G and I–P; and ventral view: B, D, F and H. ah, adductor hyoideus; am, adductor mandibulae; ao, adductor operculi; do, dilator operculi; hh, hyohyoideus; ih, interhyoideus; ima, intermandibularis anterior; imp, intermandibularis posterior; io, inferior oblique; ir, inferior rectus; lap, levator arcus palatini; lr, lateral rectus; mr, medial rectus; sh, sternohyoideus; so, superior oblique and sr, superior rectus.

360 confirm whether the defects in pharyngeal muscles in the *six1a*
 361 morphants were exclusively the result of *Six1a* loss or the result of
 362 defective mesoderm core, defective endoderm pharyngeal pouch, or

neural crest cells. To accomplish this, we detected the expressions of 363
 364 *et1*, *fgf3* and *dlx2*, which are the gene markers of the ventral mesoderm
 365 core (Miller et al., 2000), the endoderm pouch (David et al., 2002) and

Table 1

Six1 is required for the developments of medial rectus (mr), inferior rectus (ir), sternohyoideus (sh) and all arch muscles.

six1-MO-injected concentration	Defect (%)		
	Absent-muscle	Reduced-muscle	Wild-type like
Uninjected	0 (0/107)	0 (0/107)	100 (107/107)
1 ng	3.1 (3/98)	91.8 (90/98)	5.1 (5/98)
2 ng	19.0 (20/105)	76.2 (80/105)	4.8 (5/108)
4 ng	42.1 (48/114)	55.2 (63/114)	2.7 (3/114)
6 ng	65.1 (58/89)	34.9 (31/89)	0 (0/89)
8 ng	81.8 (54/66)	18.2 (12/66)	0 (0/66)

The morphological defects were observed at 72 hpf. Absent-muscle defect indicated that mr, ir, sh and ventral arch muscles were completely lost but remnants of dorsal arch muscles still remained. Reduced-muscle defect indicated that mr, ir, sh and all arch muscles were partially lost. Wild-type like phenotype indicated that the head muscles were not lost.

neural crest cells (Akimenko et al., 1994), respectively. Results showed that both *et1* (Figs. 3A vs. B), *fgf3* (Figs. 3C vs. D) and *dlx2* (Figs. 3E vs. F) were normally expressed in the *six1a*-MO-injected embryos at 36 hpf, indicating that mesoderm core, endoderm pouch and neural crest cells develop normally. The loss of pharyngeal arch muscle in *six1a* morphants does not arise from the lost structures of mesoderm core, pharyngeal pouch and neural crest cells. Therefore, we proposed that Six1a is directly involved in pharyngeal arch myogenesis.

six1a links with either *myf5* or *myod* to modulate the development of craniofacial muscles

Based on the expression patterns and the muscle defects which occurred in the *six1a* morphants, we hypothesized the plausibility of a

myf5-*six1a*-*myod* regulatory pathway in craniofacial muscle develop- 378
ment. After we confirmed the specific activities of *myf5*-MO and 379
myod-MO (Supplemental Fig. S3), we microinjected either *myf5*-MO 380
or *myod*-MO together with *six1a* mRNA to determine which embryo 381
would be rescued by *six1a* mRNA from MO-induced defect. Results 382
showed that both *myf5*- (Figs. 4E–H) and *myod*-morphants (Figs. 4I–K) 383
failed to be rescued from their muscle defects through the addition of 384
exogenous *six1a* mRNA (Wild type control, Figs. 4A, B). Therefore, we 385
next microinjected *six1a*-MO with either *myf5* mRNA or *myod* mRNA 386
to determine which mRNA enabled rescue of the embryos from the 387
defects induced by *six1a*-MO (*six1a*-MO phenotype control, Figs. 4C, 388
D). By co-injection of *six1a*-MO with *myf5* mRNA, results showed that, 389
while the loss of mr, ir and the remnants of pharyngeal arch muscle 390
were observed, muscle sh had been rescued (Figs. 4M, N; and Table 2). 391
This evidence suggests that *myf5* may not be an upstream modulator 392
of *six1a*. Instead, *myf5* and *six1a* may independently regulate the 393
craniofacial muscles derived from the head paraxial mesoderm, mr, ir 394
and the pharyngeal arch muscles. In contrast, co-injection of *myod* 395
mRNA enabled embryos to rescue all head muscle defects induced by 396
six1a-MO, suggesting that *six1a* was the upstream regulatory gene of 397
myod (Figs. 4O, P; and Table 2). 398

It is noteworthy that the muscle sh, which originates from the 399
trunk, could be rescued by *myf5* mRNA in the *six1a* morphants. Based 400
on this evidence, we hypothesized that Six1a plays roles in different 401
regulatory pathways between cranial and trunk myogenesis. To 402
demonstrate this hypothesis, we analyzed the development of the 403
sh, fin bud (fb) and posterior hypoaxial muscle (phm) that come from 404
the dermomyotome in the anterior somites. Using whole-mount *in situ* 405
hybridization, we observed that *six1a*, *myf5* and *myod* were all 406
expressed in the muscle primordia of wild-type at 36 hpf (Figs. 5B, C; 407




Fig. 3. Loss of Six1a function does not impede the normal development of mesoderm core and pharyngeal pouch. The expression patterns of *et1*, *fgf3* and *dlx2* were examined in the wild-type and in the *six1a*-MO-injected embryos at 36 hpf. Results showed that the transcripts of *et1*, *fgf3* and *dlx2* exhibited similarly in ventral mesoderm cores (A vs. B, arrows), pharyngeal pouches (C vs. D, arrows), and neural crest cells (E vs. F, six arches), respectively, between wild-type embryos and *six1a* morphants.




Fig. 4. Injection of *myod* mRNA enables embryos to rescue the defective muscle derived from cranial mesoderm in the *six1a* morphants. Embryos derived from Tg (α -actin:RFP) (A, B as non-treated) were injected with 8 ng of *six1a*-MO (C, D) and either 4 ng of *myf5*-MO (E, F) or *myod*-MO (I, J) to serve as control groups. Embryos injected with 4 ng of *myf5*-MO and 150 pg of *six1a* mRNA (G, H), 4 ng of *myod*-MO and 150 pg of *six1a* mRNA (K, L), 8 ng of *six1a*-MO and 100 pg of *myf5* mRNA (M, N), and 8 ng of *six1a*-MO and 50 pg of *myod* mRNA (O, P) were used to examine the appearance of RFP-labeled muscles. Results showed that only sr and mr/ir muscles exhibited in the *myf5*-MO-injected embryos and in the *myf5*-MO-*six1a*-mRNA-injected embryos (E vs. G and F vs. H). In contrast, only so, io, lap/do, ah, ao, and sh muscles exhibited in the *myod*-MO-injected embryos and in the *myod*-MO-*six1a*-mRNA-injected embryos (I vs. K and J vs. L). Similar to *six1a* morphants, embryos co-injected with *six1a*-MO and *myf5* mRNA exhibited the so, io, sr, lr and remnant dorsal branchial arch muscles. However, injection of *myf5* mRNA enabled embryos to rescue only sh primordia muscle among defects induced by *six1a*-MO (M, N), while injection of *myod* mRNA enabled embryos to rescue all the defective muscle primordia induced by *six1a*-MO (O, P). The rescued muscles are marked in green typeface. Lateral view: A, C, E, G, I, K, M and O; Ventral view: B, D, F, H, J, L, N and P. ah, adductor hyoideus; am, adductor mandibulae; do, dilator operculi; ah, adductor operculi; do, dilator operculi; hh, hyohyoideus; ih, interhyoideus; ima, intermandibularis anterior; imp, intermandibularis posterior; io, inferior oblique; ir, inferior rectus; lap, levator arcus palatini; lr, lateral rectus; mr, medial rectus; sh, sternohyoideus; so, superior oblique and sr, superior rectus.

408 and Supplemental Fig. S4). However, we also observed that the sh, fb
409 and phm were absent in the *six1a*-MO-injected embryos derived from
410 the transgenic line Tg (α -actin:RFP) at 72 hpf (Fig. 5D). In addition,
411 *myf5* and *myod* lost their expressions in these muscles at 36 hpf (Figs.

t2.1 **Table 2**

The loss of mr, ir and arch muscles, which originate from cranial mesoderm, in the *six1a*-morphants was rescued by *myod* mRNA, but not *myf5* mRNA.

six1-MO-injected concentration	Defect ^a (%)		
	Absent-muscle	Reduced-muscle	Wild-type like
8 ng	85.7 (66/77)	13.0 (10/77)	1.3 (1/77)
8 ng + 150 pg <i>six1</i> mRNA	20.5 (14/68)	44.1 (30/68)	35.4 (24/68)
8 ng + 250 pg <i>six1</i> mRNA	23.4 (11/47)	36.2 (17/47)	40.4 (19/47)
8 ng + 50 pg <i>myf5</i> mRNA	86.0 (49/57)	14.0 (8/57)	0 (0/57)
8 ng + 100 pg <i>myf5</i> mRNA	84.1 (53/63)	14.3 (9/63)	1.6 (1/63)
8 ng + 50 pg <i>myod</i> mRNA	21.3 (16/75)	42.7 (32/75)	36.0 (27/75)

The morphological defects were observed at 72 hpf. Absent-muscle defect indicated that mr, ir and ventral arch muscles were completely lost but the remnants of dorsal arch muscles still remained. Reduced-muscle defect indicated that mr, ir and all arch muscles were partially lost. Wild-type like phenotype indicated that the head muscles were not lost.

t2.12 ^a The sh muscle was not included because it originates from the trunk.

5E, F). Thus, we reasoned that Six1a is required for the trunk
412 migratory muscles. When *six1a*-MO was co-injected with *six1a* mRNA
413 into embryos, the sh, fb and phm primordia appeared normally at
414 72 hpf (Fig. 5G). Furthermore, both *myf5* and *myod* were detected at
415 48 hpf (Figs. 5H, I). Interestingly, co-injection of either *myf5* or *myod*
416 mRNA could rescue the defective development of sh, fb and phm
417 primordia induced by *six1a*-MO at 72 hpf (Figs. 5J, M). The expressions
418 of *myod* and *myogenin* were partially restored in the embryos co-
419 injected with *myf5* mRNA and *six1a*-MO when observed at 48 hpf
420 (Figs. 5K, L). Similarly, the expressions of *myf5* and *myogenin* were
421 also partially rescued in the embryos co-injected with *myod* mRNA
422 and *six1a*-MO (Figs. 5N, O). Thus, we concluded that *six1a* is required
423 for the expressions of *myf5* and *myod* in sh and trunk myogenesis, but
424 *six1a* activates *myf5* and *myod* through the *six1a*-*myf5* pathway and
425 *six1a*-*myod* pathway, respectively. 426

Regulatory pathways that control *six1a* expression

427
428 Six1a plays important roles in pharyngeal arch muscle, mr and ir
429 development. It has been reported that mouse T-box gene, *tbx1*, is an
430 early cranial mesoderm inducer which regulates arch muscle 430




Fig. 5. Injection of *six1a*-, *myf5*- and *myod* mRNA enables embryos to rescue trunk migratory head muscle sternohyoideus (sh) defect in *six1a* morphants. Dorsal views of embryos derived either from the transgenic line Tg(α -actin:RFP) (A, D, G, J, M) or from the wild-type (B, C, E, F, H, I, K, L). The RFP expression in the embryos derived from the transgenic line at 72 hpf (A) and the detection of *myf5* and *myod* by whole-mount *in situ* hybridization at 36 hpf (B, C) served as control groups. Injection of embryos with either 8 ng of *six1a*-MO alone (D–F) or co-injection with 8 ng of *six1a*-MO and 150 pg of *six1a* mRNA (G–I), 100 pg of *myf5* mRNA (J–L) or 50 pg of *myod* mRNA (M–O) were examined. RFP, *myf5* and *myod* were not detected in sh, fb, or phm primordia in the *six1a* morphants (D–F); however, co-injection of *six1a* mRNA enabled embryos to rescue the defective expressions of RFP, *myf5* and *myod* in sh, fb and phm primordia induced by *six1a*-MO at 48 hpf (H, I) and at 72 hpf (G). Meanwhile, injection of *myf5* mRNA enabled embryos to rescue the defective expressions of RFP, *myod* and *myogenin* in sh, fb and phm primordia induced by *six1a*-MO at 48 hpf (K, L) and at 72 hpf (J). Injection of *myod* mRNA enabled embryos to rescue the defective expressions of RFP, *myf5* and *myogenin* in sh, fb and phm primordia induced by *six1a*-MO at 48 hpf (N, O) and at 72 hpf (M). fb, fin bud; phm, posterior hypoaxial muscle; and sh, sternohyoideus.

development (Grifone and Kelly, 2007; Kelly et al., 2004; Piotrowski et al., 2003). To understand whether *tbx1* is upstream of *six1a*, we detected the expression of *tbx1* and found that *tbx1* was expressed in zebrafish pharyngeal arch region at 36 hpf (Fig. 6A). In *tbx1*-MO-injected embryos derived from the transgenic line Tg(α -actin:RFP), all the pharyngeal arch muscles were lost when observed at 72 hpf under fluorescent microscopy. However, the six extraocular muscles were normally developed (Fig. 6E). We also detected *six1a*, *myf5* and *myod* expressions in the *tbx1*-MO-injected embryos. Results showed that the expressions of *six1a*, *myf5* and *myod* were lost in pharyngeal arch muscles, but not the extraocular muscles (Figs. 6B–D), suggesting that *tbx1* is required for the expressions of *six1a*, *myf5* and *myod* in pharyngeal arch muscle. Interestingly, when

six1a-, *myf5*- or *myod* mRNA was co-injected with *tbx1*-MO, we found that *myf5*-mRNA (Fig. 6G), but not *six1a*-mRNA or *myod* mRNA, enabled rescue of embryos from the defects induced by *tbx1*-MO (Figs. 6F, H). This evidence strongly suggests that *tbx1* is an upstream modulator of *myf5*, regulating the specification of cranial muscle development through *myf5*; however, the findings also indicate that *tbx1* is not a direct upstream regulator of *six1a*.

Next, we studied whether the EYA-DACH-SIX-PAX pathway, which plays a critical function in the trunk muscle development of mouse, is also involved in the head muscle development of zebrafish. When we detected the *myf5* and *myod* expressions in the *eya1*-knockdown morphants, we found that both *myf5* (Figs. 7A vs. C) and *myod* (Figs. 7D vs. F) were normally expressed in the *eya1*-MO-injected




Fig. 6. The function of Six1a in branchial muscle development requires Tbx1 and Myf5 to play a specification role on arch muscle cell fate. Embryos derived from the wild-type strain (A–D) and from the transgenic line *Tg*(α -actin:RFP) (E–H) were examined at lateral view. Whole-mount *in situ* hybridization was used to detect the *tbx1* expression in arch muscle and cranial mesoderm in wild-type embryos at 36 hpf (A). Compared to the above control embryos, the expressions of *six1a* (B), *myf5* (C) and *myod* (D) in the 10 ng group of *tbx1*-MO-injected embryos were lost in arch muscles, but retained in extraocular muscles. We also observed that all the pharyngeal arch muscles were lost, but that 6 extraocular muscles developed normally in the 10 ng group of *tbx1*-MO-injected embryos derived from *Tg*(α -actin:RFP) at 72 hpf (E). With co-injection of 10 ng of *tbx1*-MO and either 150 pg of *six1a* mRNA (F), 100 pg of *myf5* mRNA (G) or 50 pg of *myod* mRNA (H) in embryos, we found that only *myf5* mRNA enabled embryos to rescue the RFP expression in lap, do, ah, ao, am, ima/imp and ih/hh (marked in green typeface of G). The heart defect induced by injection of *tbx1*-MO is labeled with a white star. ah, adductor hyoideus; am, adductor mandibulae; ao, adductor operculi; do, dilator operculi; hh, hyohyoideus; ih, interhyoideus; ima, intermandibularis anterior; imp, intermandibularis posterior; io, inferior oblique; ir, inferior rectus; lap, levator arcus palatini; lr, lateral rectus; mr, medial rectus; sh, sternohyoideus; so, superior oblique and sr, superior rectus. Embryos were all lateral views.

embryos. In addition, we injected *eya1*-MO into the embryos derived from transgenic line *Tg*(α -actin:RFP) and found that the head muscles were still developed normally in the *eya1* morphants (Figs. 7I, L), even though the *eya1* morphant suffered from reduced size of the inner ear (Supplemental Fig. S5), a phenotype similar to that of the *eya1* mutant described by Kozłowska et al. (2005). In contrast, when we detected the *myf5* and *myod* expressions in the *pax3*-knockdown morphants, we found that *myf5* was detected in the head muscles that originated from the mesoderm (Figs. 7A vs. B), and *myod* was detected only in so, io, sr and lr muscle primordia in the *pax3*-MO-injected embryos (Figs. 7D vs. E), suggesting that *pax3* is necessary for the development of mr and ir, all arch muscles and sh. Moreover, when we injected *pax3*-MO into the *Tg*(α -actin:RFP) embryos, we found that only the so, io, sr and lr muscles remained unchanged, which was similar to that of *six1a*-MO

morphants (Figs. 7G, H, J, K). When we co-injected *six1a* mRNA with *pax3*-MO, it was observed that the head muscle defects induced by *pax3*-MO could not be rescued (Figs. 7M, P). Similarly, neither *myf5* nor *myod* mRNA was able to rescue the *pax3*-morphant defects (Figs. 7N, O, Q, R). To better understand the role *pax3* plays in craniofacial muscle development, we analyzed the expression pattern of *pax3* by whole-mount *in situ* hybridization during late embryogenesis. Results showed that *pax3* was not detected in the cranial muscles, with the exception of sh (Supplemental Fig. S6). However, the absence of Pax3 function caused a severe defect in the head muscles. Based on this evidence, we suggest that the modulation of *pax3* on the cranial muscle development from head mesoderm is indirect in manner. It is also clear that *six1a* and *pax3* do not function in the same regulatory network during cranial muscle development.




Fig. 7. Similar to Six1a, Pax3 is required for the development of mr, ir and all arch muscles. Embryos derived from the wild-type strain (A–F) and from the transgenic line Tg(α -actin:RFP) (G–R) were examined. Whole-mount *in situ* hybridization was used to detect the expressions of *myf5* and *myod* at 48 hpf in the wild-type embryos, which served as a control group (A, D). Compared to the control group, embryos injected with 3 ng of *pax3*-MO exhibited a normal expression of *myf5* in head muscle primordia at 48 hpf (B), but these embryos expressed *myod* only in so/sr, lr, io, and some remnant branchial muscles (E). Embryos injected with 10 ng of *eya1*-MO expressed *myf5* and *myod* normally in head muscle primordia at 48 hpf (C, F). We also noticed that the RFP expression of embryos injected with *six1a*-MO was similar to that of control group at 72 hpf (G vs. J). The RFP signal appeared in the so, io, sr, lr and some remnant branchial muscles in *pax3*-MO-injected embryos, which was similar to that of the *six1a* morphants at 72 hpf (G vs. H and J vs. K). The RFP signal appeared in all cranial muscles of the *eya1*-MO-injected embryos at 72 hpf (I and L). By co-injection of 10 ng of *pax3*-MO with 150 pg of *six1a* mRNA (M, P), 100 pg of *myf5* mRNA (N, Q) or 50 pg of *myod* mRNA (O, R), we found that the defective expressions of *six1a*, *myf5* and *myod* could not be rescued in the *pax3* morphants.

487 **Discussion**

488 Myf5 and Myod play crucial functions in modulating the expression
 489 of genes encoding the muscle structural proteins and, finally,
 490 permitting the assembly of myofibers (Molkentin and Olson, 1996;
 491 Buckingham, 2001). In previous studies, we demonstrated that the
 492 role of myogenic regulatory factor *myf5* is markedly different from
 493 that of *myod* during craniofacial muscle development in zebrafish
 494 through three pathways (Lin et al., 2006). However, it remained
 495 unclear whether other factors might be involved in the regulation of
 496 *myf5* and *myod* expression in craniofacial muscle development.
 497 Here, we study the roles that transcriptional factors *six1a*, *tbx1* and
 498 *pax3* play in regulating *myf5* and *myod* expressions in craniofacial
 499 muscle development. Based on expression patterns and knockdown
 500 phenotypes, we, therefore, proposed four putative regulatory path-
 501 ways along which these myogenic regulatory factors function with
 502 particular focus on Myf5 and Myod (Fig. 8).

503 **Regulatory networks of *Tbx1*, *Six1a*, *Pax3*, *Myf5* and *Myod* during**
 504 **cranial myogenesis**

505 During zebrafish cranial muscle development, the arch I and II
 506 mesoderm cores are subdivided into dorsal and ventral mesoderm

cores. The dorsal mesoderm cores are the precursors of *lap*, *do*, *am*, *ah*,
 507 and *ao*, whereas the ventral mesoderm cores are the precursors of
 508 *ima*, *imp*, *ih*, and *hh*. We previously found that both *myf5* and *myod*
 509 are expressed in the dorsal mesoderm cores, but only *myod* is
 510 expressed in the ventral mesoderm (Lin et al., 2006). Nathan et al.
 511 (2008) also showed that chick *myf5* expresses in the dorsal region of
 512 arch I mesoderm core at an early stage and functions synergistically
 513 with *Isl1* to commit cell fates to be different from those in ventral
 514 arch I mesoderm core. 515

Pathway I is involved in dorsal arch muscle development. In this
 516 study, we demonstrate that the expressions of *myf5*, *six1a* and *myod*
 517 are not detected in the dorsal arch region of embryos treated with
 518 *tbx1*-MO. However, only injection of *myf5* mRNA can enable rescue
 519 of the embryos from the defects induced by *tbx1*-MO (Fig. 6). We
 520 therefore propose that *tbx1* determines cell fates to myogenic lineage
 521 through the modulation of *myf5*. Once *myf5* is expressed, *myod*
 522 expression starts to increase. On the other hand, we found that *myf5*
 523 was expressed normally in the embryos injected with either *six1a*- or
 524 *pax3*-MO (Figs. 2, 7), whereas *myod* (Figs. 2, 7) and *myogenin* (Fig. 2)
 525 transcripts were severely reduced in the dorsal arch of *six1a*- and
 526 *pax3*-morphants. In addition, injection of *myod* mRNA enables rescue
 527 of embryos from the defects induced only by *six1a*-MO (Figs. 3, 7).
 528 Taken together, we conclude that *six1a* and *pax3* are not involved in
 529




Fig. 8. Regulatory network model for *tbx1*, *six1a*, *pax3*, *myf5* and *myod*, which are involved in the craniofacial muscle development of zebrafish embryos. Based on the evidence presented in this study, we propose that the development of all cranial muscles of zebrafish is through four regulatory pathways, which is a modification of model presented by Lin et al. (2006). To summarize, Pathway I (marked in green): for dorsal arch muscles, *lap*, *do*, *ah*, *ao* and *am*. The myogenic regulatory factor *tbx1* activates *myf5* to initiate myogenesis. As a consequence, the basal level of *myf5* triggers *myod* expression to further myogenic processes. Subsequently, *myod*, which is directly controlled by *six1a*, but indirectly controlled by *pax3*, maintains and enhances a high level of myogenesis. Pathway II (marked in yellow): for the precursors of ventral arch muscles, *ima*, *imp*, *ih* and *hh*. Before subdivision, *tbx1* activates *myf5* expression to determine the myogenic cell fate. After subdivision, the major role of *myod* is to trigger the continuation of myogenic processes. Subsequently, *myod*, which is directly controlled by *six1a*, but indirectly controlled by *pax3*, maintains and enhances a high level of myogenesis. Pathway III (marked in red): for extraocular muscles, *mr* and *ir*. The myogenic regulatory factor *myod* initiates myogenesis, and its expression is controlled by *six1a* directly, and by *pax3* indirectly, to maintain and enhance myogenesis. Pathway IV (marked in blue): for trunk migratory head muscle, *sh*. The MRF *six1a* directly controls both *myf5* and *myod* in the myogenesis process, but *myf5* and *myod* have redundant function.

myogenesis initiation. Rather, they are required for maintaining a high level of *myod* transcripts so that myogenesis can be processed. We also notice that *myod* mRNA enables rescue of embryos from the defects induced by *six1a*-MO, but not by *pax3*-MO, suggesting that, while the expression of *myod* in the dorsal arch is directly controlled by *six1a*, it is only indirectly controlled by *pax3*, perhaps through the interaction of still unknown regulatory modules.

Pathway II is involved in ventral arch muscle development. Ventral mesodermal core primordia originate from the *myf5*-positive core and require *Tbx1* and *Myf5* to initiate myogenic lineage. In this study, we found that the expressions of *six1a* and *myod* are lost in the ventral arch region of *tbx1* morphants, but that this defect can be rescued by overexpression of *myf5* mRNA (Fig. 6). Therefore, we propose the involvement of two steps in the development of ventral arch muscle: *tbx1* initiates *myf5* expression in the beginning, and, subsequently, *six1a* enhances and maintains *myod* expression. Furthermore, similar to Pathway I in dorsal arch, we also found that the expressions of *myod* (Figs. 2, 7) and *myogenin* (Fig. 2) are severely reduced in ventral arch when embryos are injected with both *six1a*- and *pax3*-MO. Thus, we conclude that *six1a* and *pax3* are required to maintain *myod* expression in the ventral mesodermal core cells. Again, as in Pathway I, we found that overexpression of *myod* mRNA enables rescue of embryos from the defects induced only by *six1a*-MO, but not *pax3*-MO, suggesting that the regulation of *myod* in the ventral arch is directly controlled by *six1a*, but indirectly controlled by *pax3*.

Pathway III is involved in the development of extraocular muscles, *mr* and *ir*. We found that *six1a* and *myod* transcripts are detected, but not *myf5* transcript, in *mr* and *ir* (Fig. 1). Meanwhile, the expressions of *myod* (Figs. 2, 7>) and *myogenin* (Fig. 2) were lost in the *mr* and *ir* of *six1a*- and *pax3*-morphants. Injection of *myod* mRNA enables rescue of embryos from the defects induced by *six1a*-MO, but not induced by *pax3*-MO (Figs. 3, 7). Therefore, *myod* is required for the development of *mr* and *ir*, and *myod* is directly regulated by *six1a*. Interestingly, although *six1a* and *myod* transcripts are expressed in all extraocular muscles, the *so*, *io*, *sr* and *lr* are still observed in the *six1a* morphants, suggesting that other factors may be involved in controlling the development of *so*, *io*, *sr* and *lr*.

Pathway IV is involved in the development of *sh* primordia, which originates from anterior trunk somites. We found that the transcript of *sh* was lost in the *six1a* morphants, but injection of either *myf5* mRNA or *myod* mRNA enables embryos to be rescued from this defect (Fig. 5). Since *sh* muscle is derived from anterior trunk somites, the regulatory mechanisms controlling the muscle development between head and trunk paraxial mesoderm are different. This evidence suggests that *six1a* is governed by a head-specific regulatory cascade in cranial myogenesis, which is fundamentally distinct from that which is governed by a trunk-specific regulatory cascade. Taken together, we conclude that *six1a* performs its function in head muscle development, but it does so separately and by two distinct pathways, one where muscle development originates from head mesoderm and one where muscle development originates from the trunk.

Networks supporting modulation of *Six1a* and MRFs are dependent on mesoderm origin

The branchiomic muscles originate from cranial paraxial mesoderm. Knockdown of *Six1a* function results in greatly decreased expressions of *myod* and *myogenin*, while *myf5* is expressed normally. Because of the existence of *myf5* in these muscles, the remaining arch muscles in *Six1a* knockdown embryos are observed. Nevertheless, *myod* transcripts are reduced, with the result that these muscles eventually lose their function (Fig. 3). Like branchiomic muscles, the extraocular muscles originate from cranial paraxial mesoderm. Both *six1a* and *myod* transcripts are expressed in *mr* and *sr* muscles at 32 hpf, whereas *myf5* is not expressed (Fig. 2). Thus, when *six1a* is

knocked down, the *myod* transcripts are lost, with the result that muscle primordia of *mr* and *ir* are not developed (Fig. 3). On the other hand, unlike branchiomic muscles and extraocular muscles, the cranial muscle *sh* originates from trunk paraxial mesoderm, which is named dermomyotome. During *sh* muscle development, *Six1a* is required for both *myf5* and *myod* expressions (Fig. 5). This result is consistent with what we observe in *fb* and *phm* which originate from anterior trunk mesoderm in zebrafish. Therefore, both *myf5* mRNA and *myod* mRNA were injected in the attempt to rescue muscle defects of *six1a* morphants. While injection of *myf5* mRNA could rescue only the defective *sh* muscle in *six1a* morphants, injection of *myod* mRNA enabled rescue of embryos from all defective cranial muscles (Fig. 4). Based on these findings, it seems clear that the modulatory network between *Six1a* and these two MRFs in cranial paraxial mesoderm is quite different from that which is observed in trunk (*sh*) paraxial mesoderm. This conclusion is similar to, and supported by, the findings of Grifone et al. (2005) in mice. They described how *six1* and *six4* genes control *mrf4* expression and that *six1*^{-/-}*six4*^{-/-} embryos display reduced and delayed expressions of *myod* and *myogenin*, whereas the early activation of *myf5* transcripts in the epaxial somite is unaffected. However, in the limb muscles, the *Six1/4* are shown to be involved in *myf5* transcription through binding the MEF3 site in the 145-bp regulatory sequence located at -57.5 kb of *myf5* gene (Giordani et al., 2007).

The *six* genes constitute a large family of genes that are highly conserved within the animal kingdom. In mammals, six members of the *Six* family have so far been identified, and these can be divided into three subclasses designated as *Six1/2*, *Six3/6* and *Six4/5* subfamilies (Laclef et al., 2003; Seo et al., 1999). Moreover, it has been subsequently demonstrated that *Six1*, *Six2*, *Six4* and *Six5* have a similar binding specificity to the ARE/MEF3 site possessing a consensus sequence TCAGTTTC (Ohto et al., 1999; Spitz et al., 1998). In mice, the defects of muscle hypoplasia in *six1*^{-/-}*six4*^{-/-} embryos are more severe than those seen in *six1*^{-/-} embryos (Grifone et al., 2005; Laclef et al., 2003). Similarly, the reduced expression of *myf5* in the hind limb of *six1*^{-/-}*six4*^{+/-} mice is more severe than that observed in *six1*^{-/-} embryos. These lines of evidence suggest that *Six4* in myogenic progenitor cells displays a redundant function with *Six1*. Meanwhile, in zebrafish, three isoforms, *six4.1–4.3*, and their expression patterns have been defined, and *six4.2* is expressed in the presomitic mesoderm, somites and pectoral fin bud (Kobayashi et al., 2000). In addition, Bessarab et al. (2008) reported that the fast muscles differentiate abnormally in the trunk muscles of *six1a* morphants in contrast to the slow muscles which develop normally. The expression of *myogenin* is reduced in all somites in the *six1a* morphants at the 9-somite stage. However, *myogenin* increases its expression at the 10-somite stage and finally reaches its normal expression level at the 13-somite stage. In our case, we also noticed that the cranial muscles in *six1a* morphants are partially developed. Thus, we speculate that zebrafish *six4.2* may have redundant function with *six1* during muscle development of zebrafish. The zebrafish *Six4.2*, like mouse *Six4*, might partially compensate for the absence of *Six1* to activate MRFs in the trunk muscle cells. According to this hypothesis, the selective muscle hypoplasia described in *six1* morphants could result from either insufficient levels of *Six4.2* to compensate for *Six1* in the affected myogenic precursor cells or from the existence of specific *Six1* target genes.

Comparison of *Six1a*, *Pax3* and *Eya1* functions in head muscle development between zebrafish and other model animals

Genetic studies in *Drosophila* have identified that the *eyeless* (*pax*) is synergistic with DNA binding homeodomain factors, such as *sine oculis* (*so/six*), and nuclear cofactors, such as *eyes absent* (*eya*) and *dachshund* (*dach*) (Cheyette et al., 1994; Bonini et al., 1993; Mardon et al., 1994). Mutation of any gene encoding for these proteins leads

to the failure of eye formation, and even the ectopic expressions of these genes cause an additional eye formation (Bonini et al., 1997; Shen and Mardon, 1997). Dach2, Six1 and Eya2 were first described in the chick model system, and this report demonstrates that they synergistically regulate the expressions of Pax3 and MRFs during myogenesis (Heanue et al., 1999). Thereafter, mouse Six1 was found to have synergistic genetic interactions with Eya factor (Li et al., 2003), and Six1 knockout mice displayed defects in the kidney, muscle and inner ear (Ozaki et al., 2004). Li et al. (2003) concluded that binding Eya protein, which possesses phosphatase, can switch the Six1–Dach function from transcriptional repression to activation. Through this process, co-activators are recruited to regulate specific gene targets for controlling the proliferation and survival of precursor cells during mammalian organogenesis. Moreover, mouse Six and Eya genes are activated independently in the ventrolateral part of somitic dermomyotome, and the induction of Pax3 in this region also relies on the interactions between Six and Eya proteins (Grifone et al., 2007). Band-shifted assay and chromatin immunoprecipitation studies reveal that Pax3 expression is directly controlled by Six1 protein through binding to a conserved MEF3 site located in Pax3 hypaxial enhancer sequence. In zebrafish, *eya1* and *six1* are proven to act synergistically in adeno-hypophyseal cell development (Nica et al., 2006). This evidence suggests that the interaction of Six1a, Eya1 and Pax3 may be conserved among species in trunk muscle development. However, in this study, we found that the functions of Six1a, Eya1 and Pax3 in the cranial muscle development of zebrafish are different from their functions in trunk muscle development: *eya1* does not affect head muscle development, whereas the influence of *pax3* on the gene expressions of MRFs in the head muscles is similar to *six1a*.

The function of *myod* in head muscle development is directly modulated by Six1a, but not *myf5*, with the exception of sh muscle which originates from trunk muscle. When the function of either Tbx1 or Myf5 is lost, Six1a is unable to initiate myogenesis in arch muscles. Knockdown of *six1a* results in the reduction of *myod* transcripts, suggesting that the role of Six1a in arch muscle does not involve lineage of specification. Instead, Six1a activates and maintains *myod* expression in order to help the proliferation and differentiation of muscle cells. Moreover, knockdown of *tbx1* and *myf5* does not induce the defect occurring in extraocular muscles *mr* and *ir*, where *tbx1* and *myf5* are not expressed. Thus, *six1a* is capable of displaying the lineage of specification through the activation of *myod* expression.

Regarding Eya1, when we knocked down *eya1*, the expressions of *myf5* and *myod* in the head muscles of wild-type were normal, as well as the appearance of RFP in the head muscle of transgenic line (Fig. 7), suggesting that the loss of Eya1 function does not affect the cranial muscle development of zebrafish. In ZFIN, three Eya genes, Eya1, Eya3 and Eya4, are identified. The *eya1* (Sahly et al., 1999) and *eya4* (Schonberger et al., 2005) have been described as expressing in branchial arches (ba) and the developing somites (so) which are precursors of myogenic cells in zebrafish embryos. No major defects in head myogenesis were observed in the *eya1*-MO-injected embryos. Thus, we cannot exclude the possibility that either Eya4 or other Eya proteins could participate in a Six transcriptional complex which functions to activate downstream targets. Nevertheless, in zebrafish, adeno-hypophyseal cells in the *eya1* mutant maintain either an undifferentiated or de-differentiated state and therefore fail to initiate *gsud* and *pomc* expressions, suggesting that Eya1 is required for lineage-specific differentiation (Nica et al., 2006). However, knockdown of *six1* does not affect adeno-hypophyseal cells in lineage-specific differentiation steps in wild-type embryos. Nevertheless, when *six1* is knockdown in the embryos derived from *eya1* mutant, the proliferation of adeno-hypophyseal cells is affected and the specification defects are enhanced (Nica et al., 2006). Although *eya1* and *six1* are co-expressed in all adeno-hypophyseal cells, this evidence

suggests that the stratum and extent of gene regulation are different. Therefore, we conclude that Six1a plays a more dominant function than Eya1 during head muscle development of zebrafish.

Regarding Pax3, when we knocked down *pax3*, the defective phenotypes of cranial muscles were found to be similar to those of *six1a* morphants (Fig. 7). However, co-injection of *six1a*-, *myf5*- or *myod* mRNA failed to rescue the defects induced by *pax3*-MO (Fig. 7). By comparing the expression patterns among *pax3*, *six1a*, *myf5* and *myod*, it can be seen that *pax3* is not expressed in head muscle primordia (Supplemental Fig. S6). Based on these results, we suggest that the modulation of *pax3* in head muscles may be through an indirect means. Moreover, we found that *myf5* is normally expressed in the cranial muscles in *pax3* morphants, which is consistent with the result obtained from mouse *myf5* studies, demonstrating that *myf5* has a function in cranial muscle development of *splotch* mutant (Tajbakhsh et al., 1997). Again, this evidence strongly supports our hypothesis that the regulatory networks involved in craniofacial muscle development and trunk muscle development are not identical. In addition, lost FoxD3 expression in the *splotch* mutant indicates that Pax3 plays important roles in neural crest development (Dottori et al., 2001). Zebrafish *pax3* mRNA is also expressed in the cranial neural crest precursors and is required for specification of two specific lineages of neural crest, xanthophores and enteric neurons (Minchin and Hughes, 2008). In chicken, ablation of the cranial neural crests influences paraxial mesoderm migration, resulting in the abnormal patterning of head muscles. Moreover, the muscle precursor cells fail to undergo terminal myogenic differentiation (Rinon et al., 2007). Therefore, we speculate that the lost function of Pax3, which leads to induction of defective cranial muscles, may be the result of abnormal neural crest cell development. Taken together, we conclude that the interaction among Six1a, Eya1 and Pax3 in the cranial muscle development of zebrafish is processed in a pathway very different from the Eya1–Six1–Pax3 pathway observed in the trunk muscle development of other model animals.

Upstream regulators of Six1a and possible pathways involved in head muscle development

In mice and chicks, transcription factors Pitx2, Tbx1, Tcf21 (Capsulin), and Msc (MyoR) are necessary for activation of MRFs during branchiomeric myogenesis. In contrast, Wnt and BMP signaling display negative modulators in head muscle development (Grifone and Kelly, 2007). Here, we are the first to demonstrate that zebrafish Tbx1 initiates myogenesis in arch muscles through *myf5*, while *six1a* functions in head muscle development through *myod* (Fig. 6). These data strongly support our previous conclusions reported in Lin et al. (2006), which indicated that the regulatory pathways involving *myf5* and *myod* are different during head muscle development.

By using P19 cells, Petropoulos and Skerjanc (2002) reported that canonical Wnt3a/ β -catenin/Lef/TCF signaling activates the expressions of transcription factors, including Pax3, Mox1, Gli2, and Six1. In addition, Pax3 induces Six1 and Eya2 expressions in skeletal myogenesis (Ridgeway and Skerjanc, 2001). Thus, we speculate that Wnt signaling may also play an important role in head muscle development of zebrafish. Nevertheless, further study of the relationship between Wnt and Six1a during cranial myogenesis is more than justified.

Uncited reference

Tajbakhsh and Cossu, 1997

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ydbio.2009.04.029.

References

- 784
- 785 Akimenko, M.A., Ekker, M., Wegner, J., Lin, W., Westerfield, M., 1994. Combinatorial
786 expression of 3 zebrafish genes related to distal-less-part of a homeobox gene code
787 for the head. *J. Neurosci.* 14, 3475–3486.
- 788 Bessarab, D.A., Chong, S.W., Korzh, V., 2004. Expression of zebrafish *six1* during sensory
789 organ development and myogenesis. *Dev. Dyn.* 230, 781–786.
- 790 Bessarab, D.A., Chong, S.W., Srinivas, B.P., Korzh, V., 2008. *Six1a* is required for the onset
791 of fast muscle differentiation in zebrafish. *Dev. Biol.* 323, 216–228.
- 792 Bonini, N.M., Leiserson, W.M., Benzer, S., 1993. The eyes absent gene—genetic-control of
793 cell-survival and differentiation in the developing *Drosophila* eye. *Cell* 72, 379–395.
- 794 Bonini, N.M., Bui, Q.T., Gray-Board, G.L., Warrick, J.M., 1997. The *Drosophila* eyes absent
795 gene directs ectopic eye formation in a pathway conserved between flies and
796 vertebrates. *Development* 124, 4819–4826.
- 797 Bricaud, O., Collazo, A., 2006. The transcription factor *six1* inhibits neuronal and
798 promotes hair cell fate in the developing zebrafish (*Danio rerio*) inner ear. *J.*
799 *Neurosci.* 26, 10438–10451.
- 800 Buckingham, M., 2001. Skeletal muscle formation in vertebrates. *Curr. Opin. Genet. Dev.*
801 11, 440–448.
- 802 Buckingham, M., 2006. Myogenic progenitor cells and skeletal myogenesis in
803 vertebrates. *Curr. Opin. Genet. Dev.* 16, 525–532.
- 804 Chai, Y., Maxson, R.E., 2006. Recent advances in craniofacial morphogenesis. *Dev. Dyn.*
805 235, 2353–2375.
- 806 Chen, R., Amoui, M., Zhang, Z.H., Mardon, G., 1997. Dachshund and eyes absent proteins
807 form a complex and function synergistically to induce ectopic eye development in
808 *Drosophila*. *Cell* 91, 893–903.
- 809 Cheyette, B.N.R., Green, P.J., Martin, K., Garren, H., Hartenstein, V., Zipursky, S.L., 1994.
810 The *Drosophila* sine oculis locus encodes a homeodomain-containing protein
811 required for the development of the entire visual-system. *Neuron* 12, 977–996.
- 812 Dastjerdi, A., Robson, L., Walker, R., Hadley, J., Zhang, Z., Rodriguez-Niedenfuhr, M.,
813 Atalio, P., Baldini, A., Scambler, P., Francis-West, P., 2007. *Tbx1* regulation of
814 myogenic differentiation in the limb and cranial mesoderm. *Dev. Dyn.* 236,
815 353–363.
- 816 David, N.B., Saint-Etienne, L., Tsang, M., Schilling, T.F., Rosa, F.M., 2002. Requirement for
817 endoderm and FGF3 in ventral head skeleton formation. *Development* 129,
818 4457–4468.
- 819 Dong, F.Y., Sun, X.X., Liu, W., Ai, D., Klysis, E., Lu, M.F., Hadley, J., Antoni, L., Chen, L.,
820 Baldini, A., Francis-West, P., Martin, J.F., 2006. *Pitx2* promotes development of
821 splanchnic mesoderm-derived branchiomeric muscle. *Development* 133,
822 4891–4899.
- 823 Dottori, M., Gross, M.K., Labosky, P., Goulding, M., 2001. The winged-helix transcription
824 factor *Foxd3* suppresses interneuron differentiation and promotes neural crest cell
825 fate. *Development* 128, 4127–4138.
- 826 Drivenes, O., Seo, H.C., Fjose, A., 2000. Characterisation of the promoter region of the
827 zebrafish *six7* gene. *Biochim. Biophys. Acta-Gene Struct. Expr.* 1491, 240–247.
- 828 Giordani, J., Bajard, L., Demignon, J., Daubas, P., Buckingham, M., Maire, P., 2007. Six
829 proteins regulate the activation of *Myf5* expression in embryonic muscle limbs.
830 *Proc. Natl. Acad. Sci. U. S. A.* 104, 11310–11315.
- 831 Grifone, R., Kelly, R.G., 2007. Heartening news for head muscle development. *Trends*
832 *Genet.* 23, 365–369.
- 833 Grifone, R., Laclef, C., Spitz, F., Lopez, S., Demignon, J., Guidotti, J.E., Kawakami, K., Xu, P.,
834 X., Kelly, R., Petrof, B.J., Daegelen, D., Concordet, J.P., Maire, P., 2004. *Six1* and *Eya1*
835 expression can reprogram adult muscle from the slow-twitch phenotype into the
836 fast-twitch phenotype. *Mol. Cell Biol.* 24, 6253–6267.
- 837 Grifone, R., Demignon, J., Houbbron, C., Souil, E., Niro, C., Seller, M.J., Hamard, G., Maire, P.,
838 2005. *Six1* and *Six4* homeoproteins are required for *Pax3* and *Mrf* expression
839 during myogenesis in the mouse embryo. *Development* 132, 2235–2249.
- 840 Grifone, R., Demignon, J., Giordani, J., Niro, C., Souil, E., Bertin, F., Laclef, C., Xu, P.X., Maire,
841 P., 2007. *Eya1* and *Eya2* proteins are required for hypaxial somitic myogenesis in the
842 mouse embryo. *Dev. Biol.* 302, 602–616.
- 843 Heanue, T.A., Reshef, R., Davis, R.J., Mardon, G., Oliver, G., Tomarev, S., Lassar, A.B., Tabin,
844 C.J., 1999. Synergistic regulation of vertebrate muscle development by *Dach2*, *Eya2*,
845 and *Six1*, homologs of genes required for *Drosophila* eye formation. *Genes Dev.* 13,
846 3231–3243.
- 847 Kawakami, K., Ohto, H., Takizawa, T., Saito, T., 1996. Identification and expression of six
848 family genes in mouse retina. *FEBS Lett.* 393, 259–263.
- 849 Kawakami, K., Sato, S., Ozaki, H., Ikeda, K., 2000. Six family genes—structure and
850 function as transcription factors and their roles in development. *BioEssays* 22,
851 616–626.
- 852 Kelly, R.G., Jerome-Majewska, L.A., Papaioannou, V.E., 2004. The *del22q11.2* candidate
853 gene *Tbx1* regulates branchiomeric myogenesis. *Hum. Mol. Genet.* 13, 2829–2840.
- 854 Kobayashi, M., Toyama, R., Takeda, H., Dawid, B., Kawakami, K., 1998. Overexpression of
855 the forebrain-specific homeobox gene *six3* induces rostral forebrain enlargement in
856 zebrafish. *Development* 125, 2973–2982.
- 857 Kobayashi, M., Osanai, H., Kawakami, K., Yamamoto, M., 2000. Expression of three
858 zebrafish *Six4* genes in the cranial sensory placodes and the developing somites.
859 *Mech. Dev.* 98, 151–155.
- 860 Kobayashi, M., Nishikawa, K., Suzuki, T., Yamamoto, M., 2001. The homeobox protein
861 *Six3* interacts with the Groucho corepressor and acts as a transcriptional repressor
862 in eye and forebrain formation. *Dev. Biol.* 232, 315–326.
- 863 Kozłowska, D.J., Whitfield, T.T., Hukrieded, N.A., Lamb, W.K., Weinberga, E.S., 2005. The
864 zebrafish dog-eared mutation disrupts *eya1*, a gene required for cell survival and
865 differentiation in the inner ear and lateral line. *Dev. Biol.* 277, 27–41.
- 866 Laclef, C., Hamard, G., Demignon, J., Souil, E., Houbbron, C., Maire, P., 2003. Altered
867 myogenesis in *Six1*-deficient mice. *Development* 130, 2239–2252.
- Lee, H.C., Huang, H.Y., Lin, C.Y., Chen, Y.H., Tsai, H.J., 2006. *Foxd3* mediates zebrafish
868 *myf5* expression during early somitogenesis. *Dev. Biol.* 290, 359–372. 869
- Lee, H.C., Tsai, J.N., Liao, P.Y., Tsai, W.Y., Lin, K.Y., Chuang, C.C., Sun, C.K., Chang, W.C., Tsai,
870 H.J., 2007. Glycogen synthase kinase 3 α and 3 β have distinct functions during
871 cardiogenesis of zebrafish embryo. *BMC Dev. Biol.* 7, 93–107. 872
- Li, X., Oghi, K.A., Zhang, J., Krones, A., Bush, K.T., Glass, C.K., Nigam, S.K., Aggarwal, A.K.,
873 Maas, R., Rose, D.W., Rosenfeld, M.G., 2003. *Eya* protein phosphatase activity
874 regulates *Six1*-*Dach*-*Eya* transcriptional effects in mammalian organogenesis. 875
Nature 426, 247–254. 876
- Lin, C.Y., Yung, R.F., Lee, H.C., Chen, W.T., Chen, Y.H., Tsai, H.J., 2006. Myogenic regulatory
877 factors *Myf5* and *MyoD* function distinctly during craniofacial myogenesis of
878 zebrafish. *Dev. Biol.* 299, 594–608. 879
- L'Honore, A., Coulon, V., Marcil, A., Lebel, M., Lafrance-Vanasse, J., Gage, P., Camper, S.,
880 Drouin, J., 2007. Sequential expression and redundancy of *Pitx2* and *Pitx3* genes
881 during muscle development. *Dev. Biol.* 307, 421–433. 882
- Lu, J.R., Basse-Duby, R., Hawkins, A., Chang, P., Valdez, R., Wu, H., Gan, L., Shelton, J.M.,
883 Richardson, J.A., Olson, E.N., 2002. Control of facial muscle development by *MyoR*
884 and capsulin. *Science* 298, 2378–2381. 885
- Mardon, G., Solomon, N.M., Rubin, G.M., 1994. *Dachshund* encodes a nuclear-protein
886 required for normal eye and leg development in *Drosophila*. *Development* 120,
887 3473–3486. 888
- Miller, C.T., Schilling, T.F., Lee, K.H., Parker, J., Kimmel, C.B., 2000. *suherc* encodes a
889 zebrafish *Endothelin-1* required for ventral pharyngeal arch development. 890
Development 127, 3815–3828. 891
- Minchin, J.E., Hughes, S.M., 2008. Sequential actions of *Pax3* and *Pax7* drive
892 xanthophore development in zebrafish neural crest. *Dev. Biol.* 319, 530. 893
- Molkentin, J.D., Olson, E.N., 1996. Defining the regulatory networks for muscle
894 development. *Curr. Opin. Genet. Dev.* 6, 445–453. 895
- Mootosamy, R.C., Dietrich, S., 2002. Distinct regulatory cascades for head and trunk
896 myogenesis. *Development* 129, 573–583. 897
- Nica, G., Herzog, W., Sonntag, C., Nowak, M., Schwarz, H., Zapata, A.G., Hammerschmidt,
898 M., 2006. *Eya1* is required for lineage-specific in the zebrafish differentiation, but
899 not for cell survival adenohypophysis. *Dev. Biol.* 292, 189–204. 900
- Noden, D.M., Francis-West, P., 2006. The differentiation and morphogenesis of
901 craniofacial muscles. *Dev. Dyn.* 235, 1194–1218. 902
- Ohto, H., Kamada, S., Tago, K., Tominaga, S., Ozaki, H., Sato, S., Kawakami, K., 1999.
903 Cooperation of *Six* and *Eya* in activation of their target genes through nuclear
904 translocation of *Eya*. *Mol. Cell Biol.* 19, 6815–6824. 905
- Ozaki, H., Watanabe, Y., Takahashi, K., Kitamura, K., Tanaka, A., Urabe, K., Momoi, T.,
906 Sudo, K., Sakagami, J., Asano, M., Iwakura, Y., Kawakami, K., 2001. *Six4*, a putative
907 myogenin gene regulator, is not essential for mouse embryonal development. *Mol.*
908 *Cell Biol.* 21, 3343–3350. 909
- Ozaki, H., Nakamura, K., Funahashi, J., Ikeda, K., Yamada, G., Tokano, H., Okamura, H.,
910 Kitamura, K., Muto, S., Kotaki, H., Sudo, K., Horai, R., Iwakura, Y., Kawakami, K., 2004.
911 *Six1* controls patterning of the mouse otic vesicle. *Development* 131, 551–562. 912
- Petropoulos, H., Skerjanc, I.S., 2002. *beta*-catenin is essential and sufficient for skeletal
913 Myogenesis in P19 cells. *J. Biol. Chem.* 277, 15393–15399. 914
- Pignoni, F., Hu, B.R., Zavitz, K.H., Xiao, J.A., Garrity, P.A., Zipursky, S.L., 1997. The eye-
915 specification proteins *so* and *eya* form a complex and regulate multiple steps in
916 *Drosophila* eye development. *Cell* 91, 881–891. 917
- Piotrowski, T., Ahn, D.G., Schilling, T.F., Nair, S., Ruvinsky, I., Geisler, R., Rauch, G.J.,
918 Haffter, P., Zon, L.L., Zhou, Y., Foott, H., Dawid, I.B., Ho, R.K., 2003. The zebrafish *van*
919 *gogh* mutation disrupts *tbx1*, which is involved in the DiGeorge deletion syndrome
920 in humans. *Development* 130, 5043–5052. 921
- Rawls, A., Olson, E.N., 1997. *MyoD* meets its maker. *Cell* 89, 5–8. 922
- Ridgeway, A.G., Skerjanc, I.S., 2001. *Pax3* is essential for skeletal myogenesis and the
923 expression of *Six1* and *Eya2*. *J. Biol. Chem.* 276, 19033–19039. 924
- Rinon, A., Lazar, S., Marshall, H., Buchmann-Moller, S., Neufeld, A., Elhanany-Tamir, H.,
925 Taketo, M.M., Sommer, L., Krumlauf, R., Tzahor, E., 2007. Cranial neural crest cells
926 regulate head muscle patterning and differentiation during vertebrate embryogen-
927 esis. *Development* 134, 3065–3075. 928
- Ruf, R.C., Xu, P.X., Silvius, D., Otto, E.A., Beekmann, F., Muerb, U.T., Kumar, S., Neuhaus, T.J.,
929 Kemper, M.J., Raymond Jr., R.M., Brophy, P.D., Berkman, J., Gattas, M., Hyland, V., Ruf,
930 E.M., Schwartz, C., Chang, E.H., Smith, R.J., Stratakis, C.A., Weil, D., Petit, C.,
931 Hildebrandt, F., 2004. *SIX1* mutations cause branchio-oto-renal syndrome by
932 disruption of *EYA1*-*SIX1*-DNA complexes. *Proc. Natl. Acad. Sci. U. S. A.* 21, 8090–8095. 933
- Sahly, I., Andermann, P., Petit, C., 1999. The zebrafish *eya1* gene and its expression
934 pattern during embryogenesis. *Dev. Genes Evol.* 209, 399–410. 935
- Schilling, T.F., Kimmel, C.B., 1994. Segment and cell-type lineage restrictions during
936 pharyngeal arch development in the zebrafish embryo. *Development* 120, 483–494. 937
- Schonberger, J., Wang, L., Shin, T.J., Kim, S.D., Depreux, F.F.S., Zhu, H., Zon, L., Pizard, A.,
938 Kim, J.B., MacRae, C.A., Mungall, A.J., Seidman, J.G., Seidman, C.E., 2005. Mutation in
939 the transcriptional coactivator *EYA4* causes dilated cardiomyopathy and sensor-
940 ineural hearing loss. *Nat. Genet.* 37, 418–422. 941
- Seo, H.C., Saetre, B.O., Havik, B., Ellingsen, S., Fjose, A., 1998. The zebrafish *Pax3* and *Pax7*
942 homologues are highly conserved, encode multiple isoforms and show dynamic
943 segment-like expression in the developing brain. *Mech. Dev.* 70, 49–63. 944
- Seo, H.C., Curtiss, J., Mlodzik, M., Fjose, A., 1999. Six class homeobox genes in *Drosophila*
945 belong to three distinct families and are involved in head development. *Mech. Dev.*
946 83, 127–139. 947
- Shen, W.P., Mardon, G., 1997. Ectopic eye development in *Drosophila* induced by
948 directed *dachshund* expression. *Development* 124, 45–52. 949
- Shih, H.P., Gross, M.K., Kiousi, C., 2007. Cranial muscle defects of *Pitx2* mutants result
950 from specification defects in the first branchial arch. *Proc. Natl. Acad. Sci. U. S. A.*
951 104, 5907–5912. 952
- Spitz, F., Demignon, J., Porteu, A., Kahn, A., Concordet, J.P., Daegelen, D., Maire, P., 1998. 953

- 954 Expression of myogenin during embryogenesis is controlled by Six/sine oculis 966
955 homeoproteins through a conserved MEF3 binding site. *Proc. Natl. Acad. Sci. U. S. A.* 967
956 95, 14220–14225.
- 957 Tajbakhsh, S., Cossu, G., 1997. Establishing myogenic identity during somitogenesis. 968
958 *Curr. Opin. Genet. Dev.* 7, 634–641.
- 959 Tajbakhsh, S., Rocancourt, D., Cossu, G., Buckingham, M., 1997. Redefining the genetic 969
960 hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of 970
961 MyoD. *Cell* 89, 127–138.
- 962 Tirosh-Finkel, L., Elhanany, H., Rinon, A., Tzahor, E., 2006. Mesoderm progenitor cells of 971
963 common origin contribute to the head musculature and the cardiac outflow tract. 972
964 *Development* 133, 1943–1953.
- 965 Tzahor, E., Kempf, H., Mootoosamy, R.C., Poon, A.C., Abzhanov, A., Tabin, C.J., Dietrich, S., 973
Lassar, A.B., 2003. Antagonists of Wnt and BMP signaling promote the formation of 966
vertebrate dead muscle. *Genes Dev.* 17, 3087–3099. 967
von Scheven, G., Alvares, L.E., Mootoosamy, R.C., Dietrich, S., 2006. Neural tube derived 968
signals and Fgf8 act antagonistically to specify eye versus mandibular arch muscles. 969
Development 133, 2731–2745. 970
Wargelius, A., Seo, H.C., Austbo, L., Fjose, A., 2003. Retinal expression of zebrafish six3.1 971
and its regulation by Pax6. *Biochem. Biophys. Res. Commun.* 309, 475–481. 972
Xu, P.X., Adams, J., Peters, H., Brown, M.C., Heaney, S., Maas, R., 1999. Eya1-deficient mice 973
lack ears and kidneys and show abnormal apoptosis of organ primordia. *Nat. Genet.* 974
23, 113–117. 975
Xu, P.X., Zheng, W.M., Huang, L., Maire, P., Laclef, C., Silviu, D., 2003. Six1 is required for 976
the early organogenesis of mammalian kidney. *Development* 130, 3085–3094. 977

978

979

UNCORRECTED PROOF